Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
Plus components not separately reported this period.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
FAQ
- What is Enliven Therapeutics's EBIT?
- Enliven Therapeutics (ELVN) reported EBIT of -$27.82M in Q1 2026.
- How has Enliven Therapeutics's EBIT changed year-over-year?
- Enliven Therapeutics's EBIT increased by 12.2% year-over-year, from -$31.69M to -$27.82M.
- What is the long-term trend for Enliven Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Enliven Therapeutics's EBIT has grown at a 23.5% compound annual growth rate (CAGR), from -$51.44M to -$119.66M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Enliven Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude